SAN DIEGO, June 16 /CNW/ -- Nventa Biopharmaceuticals Corporation (TSX:
NVN) announced today that the Company's vice president of corporate
development, Richard Lai Fatt, Ph.D., is scheduled to present a Company
overview at the Business Forum during the Biotechnology Industry Organization
2008 International Convention being held in San Diego, California, July 17-20,
2008. The presentation will take place on Wednesday, June 18, 2008, at 3:45
p.m. PDT in Room 5B at the San Diego Convention Center.
Dr. Lai Fatt will discuss the Company's progress with its lead product
candidate, HspE7, a novel compound intended for the treatment of precancerous
and cancerous lesions caused by the human papillomavirus (HPV), one of the
most common sexually transmitted diseases in the world. The presentation will
not be webcast.
About Nventa Biopharmaceuticals Corporation:
Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV). The Company is publicly traded on the Toronto Stock
Exchange under the symbol NVN.
For more information about Nventa Biopharmaceuticals Corporation, please
visit the Company's website located at http://www.nventacorp.com.
For further information:
For further information: Donna Slade, Director, Investor Relations of
Nventa Biopharmaceuticals Corporation, +1-858-202-4945,
email@example.com; or media, Tim Brons of Vida Communication,
+1-415-675-7402, firstname.lastname@example.org; or Michael Moore of The
Equicom Group, +1-416-815-0700, ext. 241, email@example.com, both for
Nventa Biopharmaceuticals Corporation Web Site: http://www.nventacorp.com